Why stop smoking if COPD lung damage cannot be undone?

01

A smaller fall can matter even when the next lung test is lower

FEV1 is the volume exhaled in the first second of a forced breath. A level describes how much was measured at a visit; a slope describes how that measure changes over time. In the Lung Health Study's analysis of adults with mild-to-moderate airflow obstruction, sustained quitters had an initial mean improvement, followed by a slower average decline over subsequent years than continuing smokers. The later decline was not zero.

Here is a wholly fictional arithmetic example, not study data or a testing target. Across the same interval, one group's mean falls from 2.0 to 1.9 litres, while another falls from 2.0 to 1.8 litres. The losses are 0.1 and 0.2 litres: the first is smaller, but neither group has regained its starting volume. That is how preserving more function and still having a lower result can coexist. These invented values do not classify anyone's COPD or predict their next test.

The original trial randomised support programmes and study treatments, not whether each participant actually remained smoke-free. Comparisons of sustained quitters with continuing smokers therefore need that qualification. Smoking status was checked at annual visits; this is not proof of daily continuous abstinence. The findings in this selected population cannot supply an individual annual loss rate, and a spirometry trend cannot demonstrate that damaged lung structure has regrown.

[1][2]

02

An exacerbation is an event, not another name for a lung-function slope

A COPD exacerbation is a worsening episode. Research may identify it through a hospital diagnosis or an outpatient record with associated treatment, rather than by measuring FEV1. Au and colleagues' 2009 study followed a large U.S. veterans cohort; not everyone in the cohort had COPD. Among 7,109 participants reporting a physician's COPD diagnosis, former smoking was associated with fewer exacerbations after adjustment.

The result was less clear in a smaller subgroup using a stricter COPD definition: the analysis did not demonstrate a statistically significant reduction there. Severity, reasons for quitting and other behaviour can differ between former and current smokers, and records do not capture every episode in the same way. This does not erase the main association, but it prevents a promise that quitting will prevent all flare-ups, or a timetable for when a particular person's next flare-up becomes unlikely.

[3][5]

03

Lower all-cause mortality does not mean every COPD death outcome was lower

Doo and colleagues' 2023 Korean cohort analysed 1,740 men who had smoked before COPD diagnosis. The comparison was between those reporting cessation afterwards and those reporting continued smoking. Over subsequent follow-up, cessation was associated with lower adjusted all-cause and cardiovascular mortality. The COPD-specific mortality result was not statistically significant. A finding about deaths from any cause cannot be relabelled as proof about deaths specifically from COPD; nonsignificance also does not establish no possible difference.

Participants had to survive to an index point two years after diagnosis, and later smoking changes were not continuously measured. This design does not tell a newly diagnosed person to wait two years before quitting. It is observational evidence in men, subject to residual confounding, not a personal survival percentage or proof that former smokers' lungs became normal.

[4]

04

Quitting belongs alongside COPD care, not in place of it

Ongoing symptoms or existing damage are not evidence that stopping was pointless. They are reasons to keep appropriate clinical follow-up, where test trends, symptoms and exacerbations can be considered together. Do not use these studies to change an inhaler or other treatment. New or worsening breathlessness should be assessed, not automatically labelled a normal quitting effect; severe breathing difficulty calls for urgent local emergency help.

In England, NHS local stop-smoking services can help with quitting. They are not a substitute for COPD assessment or urgent respiratory care. This page explains group-level research; it does not interpret a personal lung test, set exercise or treatment targets, or calculate individual risk.

[5][6][7]

05

What to keep in mind

• Less further loss can be valuable without reversal of existing damage.
• FEV1 decline, exacerbations and mortality cannot be substituted for one another.
• Quit support and COPD care have different roles and can proceed together.